{
  "PMC": "6275699",
  "DOI": "10.2478/s11658-010-0021-5",
  "PMID": "20526748",
  "PMCID": "PMC6275699",
  "title": "Switching p53-dependent growth arrest to apoptosis via the inhibition of DNA damage-activated kinases.",
  "year": 2010,
  "source_url": "https://europepmc.org/article/PMC/PMC6275699",
  "source": "MED",
  "abstract_text": "Cisplatin and doxorubicin are widely used anticancer drugs that cause DNA damage, which activates the ATM-Chk2-p53 pathway in cancer cells. This activation leads to cell cycle block or apoptosis, depending on the nature of the DNA damage. In an attempt to enhance the effects of these agents, we inhibited ATM/ATR and Chk2, which are known upstream regulators of p53. The cancer cell lines A2780 and ARN8, bearing the wild-type p53 protein, were used to study changes in p53 activation and trans-activation. Our results suggest that the G(1)-checkpoint, normally activated by DNA damage, is functionally overcome by the action of kinase inhibitors that sensitize cells to apoptosis. Both inhibitors show these effects, albeit with variable intensity in different cell lines, which is promising for other studies and theoretically for use in clinical practice.",
  "full_text": "Cell Mol Biol Lett Cell. Mol. Biol. Lett Cellular & Molecular Biology Letters 1425-8153 1689-1392 SP Versita Heidelberg 6275699 20526748 21 10.2478/s11658-010-0021-5 Research Article Switching p53-dependent growth arrest to apoptosis via the inhibition of DNA damage-activated kinases Hublarova Pavla 1 Greplova Kristina 2 Holcakova Jitka 1 Vojtesek Borivoj 1 Hrstka Roman +420543133306 +420543211169 hrstka@mou.cz 1 1 grid.419466.8 Department of Oncological and Experimental Pathology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic 2 grid.419466.8 Department of Laboratory Medicine, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic 4 6 2010 9 2010 15 3 473 484 6 1 2010 27 5 2010 © © Versita Warsaw and Springer-Verlag Wien 2010 Cisplatin and doxorubicin are widely used anticancer drugs that cause DNA damage, which activates the ATM-Chk2-p53 pathway in cancer cells. This activation leads to cell cycle block or apoptosis, depending on the nature of the DNA damage. In an attempt to enhance the effects of these agents, we inhibited ATM/ATR and Chk2, which are known upstream regulators of p53. The cancer cell lines A2780 and ARN8, bearing the wild-type p53 protein, were used to study changes in p53 activation and trans-activation. Our results suggest that the G 1 -checkpoint, normally activated by DNA damage, is functionally overcome by the action of kinase inhibitors that sensitize cells to apoptosis. Both inhibitors show these effects, albeit with variable intensity in different cell lines, which is promising for other studies and theoretically for use in clinical practice. Key words Protein p53 ATM/ATR kinases Chk2 Inhibitors of DNA damage-activated kinases Doxorubicin Cisplatin issue-copyright-statement © © Versita Warsaw and Springer-Verlag Wien 2010 Abbreviations used cisPt cisplatin dox doxorubicin DSB double-strand break inh 1 CGK733 inhibitor ATM/ATR inh 2 Chk2 inhibitor II qRT-PCR quantitative real-time polymerase chain reaction References 1. Ko L.J. Prives C. p53: puzzle and paradigm Genes Dev. 1996 10 1054 1072 10.1101/gad.10.9.1054 8654922 2. Levine A.J. p53, the cellular gatekeeper for growth and division Cell 1997 88 323 331 10.1016/S0092-8674(00)81871-1 9039259 3. Barak Y. Juven T. Haffner R. Oren M. mdm2 expression is induced by wild type p53 activity EMBO J. 1993 12 461 468 8440237 4. Wu X. Bayle J.H. Olson D. Levine A.J. The p53-mdm-2 autoregulatory feedback loop Genes Dev. 1993 7 1126 1132 10.1101/gad.7.7a.1126 8319905 5. Lane D.P. Cancer. p53, guardian of the genome Nature 1992 358 15 16 10.1038/358015a0 1614522 6. Saito S. Goodarzi A.A. Higashimoto Y. Noda Y. Lees-Miller S.P. Appella E. Anderson C.W. ATM mediates phosphorylation at multiple p53 sites, including Ser(46), in response to ionizing radiation J. Biol. Chem. 2002 277 12491 12494 10.1074/jbc.C200093200 11875057 7. Siliciano J.D. Canman C.E. Taya Y. Sakaguchi K. Appella E. Kastan M.B. DNA damage induces phosphorylation of the amino terminus of p53 Genes Dev. 1997 11 3471 3481 10.1101/gad.11.24.3471 9407038 8. Bartek J. Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer Cancer Cell. 2003 3 421 429 10.1016/S1535-6108(03)00110-7 12781359 9. Fedier A. Schlamminger M. Schwarz V.A. Haller U. Howell S.B. Fink D. Loss of atm sensitises p53-deficient cells to topoisomerase poisons and antimetabolites Ann. Oncol. 2003 14 938 945 10.1093/annonc/mdg240 12796033 10. Shiloh Y. The ATM-mediated DNA-damage response: taking shape Trends Biochem Sci. 2006 31 402 410 10.1016/j.tibs.2006.05.004 16774833 11. Canman C.E. Wolff A.C. Chen C.Y. Fornace A.J. Jr. Kastan M.B. The p53-dependent G1 cell cycle checkpoint pathway and ataxiatelangiectasia Cancer Res. 1994 54 5054 5058 7923116 12. Canman C.E. Lim D.S. Cimprich K.A. Taya Y. Tamai K. Sakaguchi K. Appella E. Kastan M.B. Siliciano J.D. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53 Science 1998 281 1677 1679 10.1126/science.281.5383.1677 9733515 13. Banin S. Moyal L. Shieh S. Taya Y. Anderson C.W. Chessa L. Smorodinsky N.I. Prives C. Reiss Y. Shiloh Y. Ziv Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage Science 1998 281 1674 1677 10.1126/science.281.5383.1674 9733514 14. Hirao A. Kong Y.Y. Matsuoka S. Wakeham A. Ruland J. Yoshida H. Liu D. Elledge S.J. Mak T.W. DNA damage-induced activation of p53 by the checkpoint kinase Chk2 Science 2000 287 1824 1827 10.1126/science.287.5459.1824 10710310 15. Lin W.C. Lin F.T. Nevins J.R. Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation Genes Dev. 2001 15 1833 1844 11459832 16. Muller P. Ceskova P. Vojtesek B. Hsp90 is essential for restoring cellular functions of temperature-sensitive p53 mutant protein but not for stabilization and activation of wild-type p53: implications for cancer therapy J. Biol. Chem. 2005 280 6682 6691 10.1074/jbc.M412767200 15613472 17. Vojtesek B. Bartek J. Midgley C.A. Lane D.P. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53 J. Immunol. Methods 1992 151 237 244 10.1016/0022-1759(92)90122-A 1378473 18. Blaydes J.P. Hupp T.R. DNA damage triggers DRB-resistant phosphorylation of human p53 at the CK2 site Oncogene 1998 17 1045 1052 10.1038/sj.onc.1202014 9747884 19. Chen J. Marechal V. Levine A.J. Mapping of the p53 and mdm-2 interaction domains Mol. Cell Biol. 1993 13 4107 4114 7686617 20. Sheard M.A. Krammer P.H. Zaloudik J. Fractionated gamma-irradiation renders tumour cells more responsive to apoptotic signals through CD95 Br. J. Cancer 1999 80 1689 1696 10.1038/sj.bjc.6690585 10468284 21. Sheard M.A. Vojtesek B. Janakova L. Kovarik J. Zaloudik J. Upregulation of Fas (CD95) in human p53wild-type cancer cells treated with ionizing radiation Int. J. Cancer 1997 73 757 762 10.1002/(SICI)1097-0215(19971127)73:5<757::AID-IJC24>3.0.CO;2-1 9398058 22. Wang D. Lippard S.J. Cellular processing of platinum anticancer drugs Nat. Rev. Drug Discov. 2005 4 307 320 10.1038/nrd1691 15789122 23. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance Oncogene 2003 22 7265 7279 10.1038/sj.onc.1206933 14576837 24. Kurz E.U. Douglas P. Lees-Miller S.P. Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species J. Biol. Chem. 2004 279 53272 53281 10.1074/jbc.M406879200 15489221 25. McHugh P.J. Spanswick V.J. Hartley J.A. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance Lancet Oncol. 2001 2 483 490 10.1016/S1470-2045(01)00454-5 11905724 26. Kartalou M. Essigmann J.M. Recognition of cisplatin adducts by cellular proteins Mutat. Res. 2001 478 1 21 11406166 27. Chaney S.G. Campbell S.L. Bassett E. Wu Y. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts Crit Rev. Oncol. Hematol. 2005 53 3 11 10.1016/j.critrevonc.2004.08.008 15607931 28. Dronkert M.L. Kanaar R. Repair of DNA interstrand cross-links Mutat. Res. 2001 486 217 247 11516927 29. Damia G. Filiberti L. Vikhanskaya F. Carrassa L. Taya Y. D’Incalci M. Broggini M. Cisplatinum and taxol induce different patterns of p53 phosphorylation Neoplasia 2001 3 10 16 10.1038/sj.neo.7900122 11326311 30. Khanna K.K. Keating K.E. Kozlov S. Scott S. Gatei M. Hobson K. Taya Y. Gabrielli B. Chan D. Lees-Miller S.P. Lavin M.F. ATM associates with and phosphorylates p53: mapping the region of interaction Nat. Genet. 1998 20 398 400 10.1038/3882 9843217 31. Lakin N.D. Hann B.C. Jackson S.P. The ataxia-telangiectasia related protein ATR mediates DNA-dependent phosphorylation of p53 Oncogene 1999 18 3989 3995 10.1038/sj.onc.1202973 10435622 32. Tibbetts R.S. Brumbaugh K.M. Williams J.M. Sarkaria J.N. Cliby W.A. Shieh S.Y. Taya Y. Prives C. Abraham R.T. A role for ATR in the DNA damage-induced phosphorylation of p53 Genes Dev. 1999 13 152 157 10.1101/gad.13.2.152 9925639 33. Chehab N.H. Malikzay A. Appel M. Halazonetis T.D. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53 Genes Dev. 2000 14 278 288 10673500 34. Chehab N.H. Malikzay A. Stavridi E.S. Halazonetis T.D. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage Proc. Natl. Acad. Sci. U. S. A. 1999 96 13777 13782 10.1073/pnas.96.24.13777 10570149 35. Shieh S.Y. Ikeda M. Taya Y. Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2 Cell 1997 91 325 334 10.1016/S0092-8674(00)80416-X 9363941 36. Delia D. Fontanella E. Ferrario C. Chessa L. Mizutani S. DNA damage-induced cell-cycle phase regulation of p53 and p21waf1 in normal and ATM-defective cells Oncogene 2003 22 7866 7869 10.1038/sj.onc.1207086 14586414 37. Hill R. Bodzak E. Blough M.D. Lee P.W. p53 Binding to the p21 promoter is dependent on the nature of DNA damage Cell Cycle 2008 7 2535 2543 18719376 38. Noda A. Ning Y. Venable S.F. Pereira-Smith O.M. Smith J.R. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen Exp. Cell Res. 1994 211 90 98 10.1006/excr.1994.1063 8125163 39. Lu Y. Tatsuka M. Takebe H. Yagi T. Involvement of cyclin-dependent kinases in doxorubicin-induced apoptosis in human tumor cells Mol. Carcinog. 2000 29 1 7 10.1002/1098-2744(200009)29:1<1::AID-MC1>3.0.CO;2-A 11020241 40. Lu Y. Yamagishi N. Yagi T. Takebe H. Mutated p21(WAF1/CIP1/SDI1) lacking CDK-inhibitory activity fails to prevent apoptosis in human colorectal carcinoma cells Oncogene 1998 16 705 712 10.1038/sj.onc.1201585 9488034 41. Luo Y. Hurwitz J. Massague J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1 Nature 1995 375 159 161 10.1038/375159a0 7753174 42. Tang J.J. Shen C. Lu Y.J. Requirement for pre-existing of p21 to prevent doxorubicin-induced apoptosis through inhibition of caspase-3 activation Mol. Cell Biochem. 2006 291 139 144 10.1007/s11010-006-9206-7 16909308 43. Crescenzi E. Palumbo G. de Boer J. Brady H.J. Ataxia telangiectasia mutated and p21CIP1 modulate cell survival of drug-induced senescent tumor cells: implications for chemotherapy Clin. Cancer Res. 2008 14 1877 1887 10.1158/1078-0432.CCR-07-4298 18347191",
  "plain_text": "Cisplatin and doxorubicin are widely used anticancer drugs that cause DNA damage, which activates the ATM-Chk2-p53 pathway in cancer cells. This activation leads to cell cycle block or apoptosis, depending on the nature of the DNA damage. In an attempt to enhance the effects of these agents, we inhibited ATM/ATR and Chk2, which are known upstream regulators of p53. The cancer cell lines A2780 and ARN8, bearing the wild-type p53 protein, were used to study changes in p53 activation and trans-activation. Our results suggest that the G 1 -checkpoint, normally activated by DNA damage, is functionally overcome by the action of kinase inhibitors that sensitize cells to apoptosis. Both inhibitors show these effects, albeit with variable intensity in different cell lines, which is promising for other studies and theoretically for use in clinical practice."
}
